978 research outputs found
A phase transition in a system driven by coloured noise
For a system driven by coloured noise, we investigate the activation energy of escape, and the dynamics during the escape. We have performed analogue experiments to measure the change in activation energy as the power spectrum of the noise varies. An adiabatic approach based on path integral theory allows us to calculate analytically the critical value at which a phase transition in the activation energy occurs
Large fluctuations and irreversibility in nonequilibrium systems.
Large rare fluctuations in a nonequilibrium system are investigated theoretically and by analogue electronic experiment. It is emphasized that the optimal paths calculated via the eikonal approximation of the Fokker-Planck equation can be identified with the locus of the ridges of the prehistory probability distributions which can be calculated and measured experimentally for paths terminating at a given final point in configuration sspace. The pattern of optimal paths and its singularities, such as caustics, cusps and switching lines has been calculated and measured experimentally for a periodically driven overdamped oscillator, yielding results that are shown to be in good agreement with each other
Symmetry breaking of fluctuation dynamics by noise color.
Activated escape is investigated for systems that are driven by noise whose power spectrum peaks at a finite frequency. Analytic theory and analog and digital experiments show that the system dynamics during escape exhibit a symmetry-breaking transition as the width of the fluctuational spectral peak is varied. For double-well potentials, even a small asymmetry may result in a parametrically large difference of the activation energies for escape from different wells
Stochastic resonance in Gaussian quantum channels
We determine conditions for the presence of stochastic resonance in a lossy
bosonic channel with a nonlinear, threshold decoding. The stochastic resonance
effect occurs if and only if the detection threshold is outside of a "forbidden
interval". We show that it takes place in different settings: when transmitting
classical messages through a lossy bosonic channel, when transmitting over an
entanglement-assisted lossy bosonic channel, and when discriminating channels
with different loss parameters. Moreover, we consider a setting in which
stochastic resonance occurs in the transmission of a qubit over a lossy bosonic
channel with a particular encoding and decoding. In all cases, we assume the
addition of Gaussian noise to the signal and show that it does not matter who,
between sender and receiver, introduces such a noise. Remarkably, different
results are obtained when considering a setting for private communication. In
this case the symmetry between sender and receiver is broken and the "forbidden
interval" may vanish, leading to the occurrence of stochastic resonance effects
for any value of the detection threshold.Comment: 17 pages, 6 figures. Manuscript improved in many ways. New results on
private communication adde
Nonconventional stochastic resonance.
It is argued, on the basis of linear response theory (LRT), that new types of stochastic resonance (SR) are to be anticipated in diverse systems, quite different from the one most commonly studied to date, which has a static double-well potential and is driven by a net force equal to the sum of periodic and stochastic terms. On this basis, three new nonconventional forms of SR are predicted, sought, found, and investigated both theoretically and by analogue electronic experiment: (a) in monostable systems; (b) in bistable systems with periodically modulated noise; and (c) in a system with coexisting periodic attractors. In each case, it is shown that LRT can provide a good quantitative description of the experimental results for sufficiently weak driving fields. It is concluded that SR is a much more general phenomenon than has hitherto been appreciated
Recommended from our members
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249).
BackgroundS0931 is assessing recurrence-free survival in renal cell carcinoma (RCC) patients randomized to receive everolimus (EVE) versus placebo for one year following nephrectomy. Due to a higher than expected dropout rate, we assessed EVE trough levels in the adjuvant setting to evaluate the relationship between EVE exposure and probability of toxicity.MethodsPatients received 10 mg daily EVE for nine 6-week cycles. Pre-dose whole blood samples were collected pre-cycle 2 and pre-cycle 3 and analyzed for EVE. Patients with pre-cycle 2 and/or pre-cycle 3 EVE results were used in the analysis. Patients were segregated into quartiles (Q) based on EVE levels and logistic regression was used to model the most common adverse event outcomes using EVE trough as a predictor. Hazard and odds ratios were adjusted for age, BMI and performance status.ResultsA total of 467 patients were included in this analysis. Quartiles normalized to an EVE dose of 10 mg/day wereâ<â9.0, 9.0-12.9, 12.9-22.8, andâ>â22.8 ng/mL, respectively. EVE trough levels increased with increasing age (pâ<â0.001). Furthermore, EVE trough levels were higher in men than women (19.4 versus 15.4 ng/mL, pâ=â0.01). Risk of grade 2â+âtriglycerides was increased in Q2 and Q3 vs Q1 (ORâ=â2.08; pâ=â0.02 and ORâ=â2.63; pâ=â0.002). Risk of grade 2â+ârash was increased in Q2 and Q4 vs Q1 (ORâ=â2.99; pâ=â0.01 and ORâ=â2.90; pâ=â0.02). There was also an increased risk of any grade 3â+âtox in Q2 vs Q1 (ORâ=â1.71; pâ=â0.05).ConclusionsWe identified significant gender and age-related differences in EVE trough levels in patients receiving adjuvant treatment for RCC. Furthermore, our analysis identified significant associations between EVE exposure and probability of toxicity
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly
Gender Differences in Russian Colour Naming
In the present study we explored Russian colour naming in a web-based psycholinguistic experiment
(http://www.colournaming.com). Colour singletons representing the Munsell Color Solid (N=600 in total) were presented on a computer monitor and named using an unconstrained colour-naming method. Respondents were
Russian speakers (N=713). For gender-split equal-size samples (NF=333, NM=333) we estimated and compared (i)
location of centroids of 12 Russian basic colour terms (BCTs); (ii) the number of words in colour descriptors; (iii) occurrences of BCTs most frequent non-BCTs. We found a close correspondence between femalesâ and malesâ
BCT centroids. Among individual BCTs, the highest inter-gender agreement was for seryj âgreyâ and goluboj
âlight blueâ, while the lowest was for sinij âdark blueâ and krasnyj âredâ. Females revealed a significantly richer repertory of distinct colour descriptors, with great variety of monolexemic non-BCTs and âfancyâ colour names; in comparison, males offered relatively more BCTs or their compounds. Along with these measures, we gauged
denotata of most frequent CTs, reflected by linguistic segmentation of colour space, by employing a synthetic
observer trained by gender-specific responses. This psycholinguistic representation revealed femalesâ more
refined linguistic segmentation, compared to males, with higher linguistic density predominantly along the redgreen axis of colour space
Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers
Background.
The frequency with which targeted tumor sequencing results will lead to implemented change in care is unclear. Prospective assessment of the feasibility and limitations of using genomic sequencing is critically important.
Methods.
A prospective clinical study was conducted on 100 patients with diverse-histology, rare, or poor-prognosis cancers to evaluate the clinical actionability of a Clinical Laboratory Improvement Amendments (CLIA)-certified, comprehensive genomic profiling assay (FoundationOne), using formalin-fixed, paraffin-embedded tumors. The primary objectives were to assess utility, feasibility, and limitations of genomic sequencing for genomically guided therapy or other clinical purpose in the setting of a multidisciplinary molecular tumor board.
Results.
Of the tumors from the 92 patients with sufficient tissue, 88 (96%) had at least one genomic alteration (average 3.6, range 0â10). Commonly altered pathways included p53 (46%), RAS/RAF/MAPK (rat sarcoma; rapidly accelerated fibrosarcoma; mitogen-activated protein kinase) (45%), receptor tyrosine kinases/ligand (44%), PI3K/AKT/mTOR (phosphatidylinositol-4,5-bisphosphate 3-kinase; protein kinase B; mammalian target of rapamycin) (35%), transcription factors/regulators (31%), and cell cycle regulators (30%). Many low frequency but potentially actionable alterations were identified in diverse histologies. Use of comprehensive profiling led to implementable clinical action in 35% of tumors with genomic alterations, including genomically guided therapy, diagnostic modification, and trigger for germline genetic testing.
Conclusion.
Use of targeted next-generation sequencing in the setting of an institutional molecular tumor board led to implementable clinical action in more than one third of patients with rare and poor-prognosis cancers. Major barriers to implementation of genomically guided therapy were clinical status of the patient and drug access. Early and serial sequencing in the clinical course and expanded access to genomically guided early-phase clinical trials and targeted agents may increase actionability.
Implications for Practice:
Identification of key factors that facilitate use of genomic tumor testing results and implementation of genomically guided therapy may lead to enhanced benefit for patients with rare or difficult to treat cancers. Clinical use of a targeted next-generation sequencing assay in the setting of an institutional molecular tumor board led to implementable clinical action in over one third of patients with rare and poor prognosis cancers. The major barriers to implementation of genomically guided therapy were clinical status of the patient and drug access both on trial and off label. Approaches to increase actionability include early and serial sequencing in the clinical course and expanded access to genomically guided early phase clinical trials and targeted agents
Samarium-153-EDTMP (QuadrametÂź) With or Without Vaccine in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 2 Trial
PSA-TRICOM is a therapeutic vaccine in late stage clinical testing in metastatic castration-resistant prostate cancer (mCRPC). Samarium-153-ethylene diamine tetramethylene phosphonate (Sm-153-EDTMP; QuadrametÂź), a radiopharmaceutical, binds osteoblastic bone lesions and emits beta particles causing local tumor cell destruction. Preclinically, Sm-153-EDTMP alters tumor cell phenotype facilitating immune-mediated killing. This phase 2 multi-center trial randomized patients to Sm-153-EDTMP alone or with PSA-TRICOM vaccine. Eligibility required mCRPC, bone metastases, prior docetaxel and no visceral disease. The primary endpoint was the proportion of patients without radiographic disease progression at 4 months. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and immune responses. Forty-four patients enrolled. Eighteen and 21 patients were evaluable for the primary endpoint in Sm-153-EDTMP alone and combination arms, respectively. There was no statistical difference in the primary endpoint, with two of 18 (11.1%) and five of 21 (23.8%) in Sm-153-EDTMP alone and combination arms, respectively, having stable disease at approximately the 4-month evaluation time point (P = 0.27). Median PFS was 1.7 vs. 3.7 months in the Sm-153-EDTMP alone and combination arms (P = 0.041, HR = 0.51, P = 0.046). No patient in the Sm-153-EDTMP alone arm achieved prostate-specific antigen (PSA) decline \u3e 30% compared with four patients (of 21) in the combination arm, including three with PSA decline \u3e 50%. Toxicities were similar between arms and related to number of Sm-153-EDTMP doses administered. These results provide the rationale for clinical evaluation of new radiopharmaceuticals, such as Ra-223, in combination with PSA-TRICOM
- âŠ